世界のブロックバスター腫瘍学ブランド市場は、2024年に1,027.3億米ドルと評価され、2035年までに2,440.6億米ドルに達すると予測されており、予測期間（2024〜2035年）中の年平均成長率（CAGR）は8.00％で拡大すると見込まれています。過去10年間にわたり、腫瘍学は医薬品分野で最もダイナミックなセグメントの一つとなっており、前例のない科学的イノベーション、革新的な免疫療法の進展、そして個別化医療の継続的な追求によって加速されてきました。その過程で、世界中で増加し続けるがんの発症および複雑化に直面する中、Opdivo、Keytruda、Perjeta、Ibranceなどのブロックバスター腫瘍学ブランドが登場し、肺がん、リンパ腫、その他の悪性腫瘍における治療パラダイムの変革を早めてきました。
これら高額医薬品に対する需要の急増は、免疫チェックポイント阻害薬、標的生物薬、次世代の併用療法の進歩によって推進されています。それぞれのブランドは、作用機序の差別化および広範な臨床的検証を通じて、腫瘍学領域における独自のポジションを確立しています。しかし、これらのブランドの商業的成功は、臨床的有効性だけでなく、新規適応症の取得や複数地域での積極的な規制承認の追求を含む優れた商業化戦略にも依存しています。このような状況により、競争環境はイノベーションとハイステークスの方向に傾いており、市場投入のスピードやライフサイクル管理が持続的な市場リーダーシップの主要な決定要因となっています。
一方、世界的には、腫瘍学治療に関連する高コストが医療システムに大きな負担をもたらしており、価値に基づくケアモデルの構築、バイオシミラーの導入の迅速化、患者アクセスプログラムの新しい枠組みの確立が進められています。したがって、ブロックバスター腫瘍学ブランド市場は、最先端の科学と実務的な市場アクセス手法との間で均衡を見出す戦略的変革期に入りつつあり、革新的な治療が承認されるだけでなく、世界中の病院および小売薬局チャネルで十分な普及を得ることを目指しています。
Merck & Co.、Bristol Myers Squibb、Roche Holding AG、Pfizer Inc.、AstraZeneca plc、Novartis AG、Amgen Inc.、Eli Lilly and Company、Johnson & Johnson、Sanofi S.A.
目次
Chapter 1. Market Snapshot
1.1. Market Definition & Report Overview
1.2. Market Segmentation
1.3. Key Takeaways
1.3.1. Top Investment Pockets
1.3.2. Top Winning Strategies
1.3.3. Market Indicators Analysis
1.3.4. Top Impacting Factors
1.4. Application Ecosystem Analysis
1.4.1. 360’ Analysis
Chapter 2. Executive Summary
2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Market Attractiveness Analysis (top leader’s point of view on the market)
2.5. Key Findings
Chapter 3. Research Methodology
3.1. Research Objective
3.2. Supply Side Analysis
3.2.1. Primary Research
3.2.2. Secondary Research
3.3. Demand Side Analysis
3.3.1. Primary Research
3.3.2. Secondary Research
3.4. Forecasting Models
3.4.1. Assumptions
3.4.2. Forecasts Parameters
3.5. Competitive breakdown
3.5.1. Market Positioning
3.5.2. Competitive Strength
3.6. Scope of the Study
3.6.1. Research Assumption
3.6.2. Inclusion & Exclusion
3.6.3. Limitations
Chapter 4. Industry Landscape
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Porter’s 5 Forces Model
4.2.1. Bargaining Power of Buyer
4.2.2. Bargaining Power of Supplier
4.2.3. Threat of New Entrants
4.2.4. Threat of Substitutes
4.2.5. Competitive Rivalry
4.3. Value Chain Analysis
4.4. PESTEL Analysis
4.5. Pricing Analysis and Trends
4.6. Key growth factors and trends analysis
4.7. Market Share Analysis (2024)
4.8. Top Winning Strategies (2024)
4.9. Trade Data Analysis (Import Export)
4.10. Regulatory Guidelines
4.11. Historical Data Analysis
4.12. Analyst Recommendation & Conclusion
Chapter 5. Global Blockbuster Oncology Brands Market Size & Forecasts by Brands 2024-2035
5.1. Market Overview
5.1.1. Market Size and Forecast By Brands 2024-2035
5.2. Opdivo
5.2.1. Market definition, current market trends, growth factors, and opportunities
5.2.2. Market size analysis, by region, 2024-2035
5.2.3. Market share analysis, by country, 2024-2035
5.3. Keytruda
5.3.1. Market definition, current market trends, growth factors, and opportunities
5.3.2. Market size analysis, by region, 2024-2035
5.3.3. Market share analysis, by country, 2024-2035
5.4. Perjeta
5.4.1. Market definition, current market trends, growth factors, and opportunities
5.4.2. Market size analysis, by region, 2024-2035
5.4.3. Market share analysis, by country, 2024-2035
5.5. Ibrance
5.5.1. Market definition, current market trends, growth factors, and opportunities
5.5.2. Market size analysis, by region, 2024-2035
5.5.3. Market share analysis, by country, 2024-2035
Chapter 6. Global Blockbuster Oncology Brands Market Size & Forecasts by Treatment 2024-2035
6.1. Market Overview
6.1.1. Market Size and Forecast By Treatment 2024-2035
6.2. Lung Cancer
6.2.1. Market definition, current market trends, growth factors, and opportunities
6.2.2. Market size analysis, by region, 2024-2035
6.2.3. Market share analysis, by country, 2024-2035
6.3. Lymphoma
6.3.1. Market definition, current market trends, growth factors, and opportunities
6.3.2. Market size analysis, by region, 2024-2035
6.3.3. Market share analysis, by country, 2024-2035
Chapter 7. Global Blockbuster Oncology Brands Market Size & Forecasts by Distribution Channel 2024-2035
5.1. Market Overview
7.1.1. Market Size and Forecast By Brands 2024-2035
7.2. Hospital Pharmacy
7.2.1. Market definition, current market trends, growth factors, and opportunities
7.2.2. Market size analysis, by region, 2024-2035
7.2.3. Market share analysis, by country, 2024-2035
7.3. Retail Pharmacy
7.3.1. Market definition, current market trends, growth factors, and opportunities
7.3.2. Market size analysis, by region, 2024-2035
7.3.3. Market share analysis, by country, 2024-2035
7.4. Others
7.4.1. Market definition, current market trends, growth factors, and opportunities
7.4.2. Market size analysis, by region, 2024-2035
7.4.3. Market share analysis, by country, 2024-2035
Chapter 8. Global Blockbuster Oncology Brands Market Size & Forecasts by Region 2024-2035
8.1. Regional Overview 2024-2035
8.2. Top Leading and Emerging Nations
8.3. North America Blockbuster Oncology Brands Market
8.3.1. U.S. Blockbuster Oncology Brands Market
8.3.1.1. Brands breakdown size & forecasts, 2024-2035
8.3.1.2. Treatment breakdown size & forecasts, 2024-2035
8.3.1.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.3.2. Canada Blockbuster Oncology Brands Market
8.3.2.1. Brands breakdown size & forecasts, 2024-2035
8.3.2.2. Treatment breakdown size & forecasts, 2024-2035
8.3.2.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.3.3. Mexico Blockbuster Oncology Brands Market
8.3.3.1. Brands breakdown size & forecasts, 2024-2035
8.3.3.2. Treatment breakdown size & forecasts, 2024-2035
8.3.3.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.4. Europe Blockbuster Oncology Brands Market
8.4.1. UK Blockbuster Oncology Brands Market
8.4.1.1. Brands breakdown size & forecasts, 2024-2035
8.4.1.2. Treatment breakdown size & forecasts, 2024-2035
8.4.1.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.4.2. Germany Blockbuster Oncology Brands Market
8.4.2.1. Brands breakdown size & forecasts, 2024-2035
8.4.2.2. Treatment breakdown size & forecasts, 2024-2035
8.4.2.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.4.3. France Blockbuster Oncology Brands Market
8.4.3.1. Brands breakdown size & forecasts, 2024-2035
8.4.3.2. Treatment breakdown size & forecasts, 2024-2035
8.4.3.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.4.4. Spain Blockbuster Oncology Brands Market
8.4.4.1. Brands breakdown size & forecasts, 2024-2035
8.4.4.2. Treatment breakdown size & forecasts, 2024-2035
8.4.4.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.4.5. Italy Blockbuster Oncology Brands Market
8.4.5.1. Brands breakdown size & forecasts, 2024-2035
8.4.5.2. Treatment breakdown size & forecasts, 2024-2035
8.4.5.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.4.6. Rest of Europe Blockbuster Oncology Brands Market
8.4.6.1. Brands breakdown size & forecasts, 2024-2035
8.4.6.2. Treatment breakdown size & forecasts, 2024-2035
8.4.6.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.5. Asia Pacific Blockbuster Oncology Brands Market
8.5.1. China Blockbuster Oncology Brands Market
8.5.1.1. Brands breakdown size & forecasts, 2024-2035
8.5.1.2. Treatment breakdown size & forecasts, 2024-2035
8.5.1.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.5.2. India Blockbuster Oncology Brands Market
8.5.2.1. Brands breakdown size & forecasts, 2024-2035
8.5.2.2. Treatment breakdown size & forecasts, 2024-2035
8.5.2.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.5.3. Japan Blockbuster Oncology Brands Market
8.5.3.1. Brands breakdown size & forecasts, 2024-2035
8.5.3.2. Treatment breakdown size & forecasts, 2024-2035
8.5.3.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.5.4. Australia Blockbuster Oncology Brands Market
8.5.4.1. Brands breakdown size & forecasts, 2024-2035
8.5.4.2. Treatment breakdown size & forecasts, 2024-2035
8.5.4.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.5.5. South Korea Blockbuster Oncology Brands Market
8.5.5.1. Brands breakdown size & forecasts, 2024-2035
8.5.5.2. Treatment breakdown size & forecasts, 2024-2035
8.5.5.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.5.6. Rest of APAC Blockbuster Oncology Brands Market
8.5.6.1. Brands breakdown size & forecasts, 2024-2035
8.5.6.2. Treatment breakdown size & forecasts, 2024-2035
8.5.6.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.6. LAMEA Blockbuster Oncology Brands Market
8.6.1. Brazil Blockbuster Oncology Brands Market
8.6.1.1. Brands breakdown size & forecasts, 2024-2035
8.6.1.2. Treatment breakdown size & forecasts, 2024-2035
8.6.1.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.6.2. Argentina Blockbuster Oncology Brands Market
8.6.2.1. Brands breakdown size & forecasts, 2024-2035
8.6.2.2. Treatment breakdown size & forecasts, 2024-2035
8.6.2.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.6.3. UAE Blockbuster Oncology Brands Market
8.6.3.1. Brands breakdown size & forecasts, 2024-2035
8.6.3.2. Treatment breakdown size & forecasts, 2024-2035
8.6.3.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.6.4. Saudi Arabia (KSA Blockbuster Oncology Brands Market
8.6.4.1. Brands breakdown size & forecasts, 2024-2035
8.6.4.2. Treatment breakdown size & forecasts, 2024-2035
8.6.4.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.6.5. Africa Blockbuster Oncology Brands Market
8.6.5.1. Brands breakdown size & forecasts, 2024-2035
8.6.5.2. Treatment breakdown size & forecasts, 2024-2035
8.6.5.3. Distribution Channel breakdown size & forecasts, 2024-2035
8.6.6. Rest of LAMEA Blockbuster Oncology Brands Market
8.6.6.1. Brands breakdown size & forecasts, 2024-2035
8.6.6.2. Treatment breakdown size & forecasts, 2024-2035
8.6.6.3. Distribution Channel breakdown size & forecasts, 2024-2035
Chapter 9. Company Profiles
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Merck & Co.
9.2.1.1. Company Overview
9.2.1.2. Key Executives
9.2.1.3. Company Snapshot
9.2.1.4. Financial Performance (Subject to Data Availability)
9.2.1.5. Product/Services Port
9.2.1.6. Recent Development
9.2.1.7. Market Strategies
9.2.1.8. SWOT Analysis
9.2.2. Bristol Myers Squibb
9.2.3. Roche Holding AG
9.2.4. Pfizer Inc.
9.2.5. AstraZeneca plc
9.2.6. Novartis AG
9.2.7. Amgen Inc.
9.2.8. Eli Lilly and Company
9.2.9. Johnson & Johnson
9.2.10. Sanofi S.A.
